reason report
ignite- dmd market solid gene therapi initi
bottom line initi coverag solid bioscienc
op rate pt encourag preclin
data gener lead gene therapi program
duchenn muscular dystrophi dmd believ optim
pangenotyp drug candid systemat bred stabil
muscl forc develop mice decad could translat
meaning result cur potenti address almost patient
dmd
although began experi public compani
controversi due compound concern preclin
safeti manufactur resign scientif advisori
board sab member retain attract clinic
market potenti view believ issu either
adequ address case preclin safeti
manufactur necessarili directli relat sldb gene
therapi program case jame wilson sab resign
remain optimist base advanc microdystrophin
construct posit safeti read-through avx nr gene
therapi program use vector posit
preclin data resolut manufactur constraint
advanc microdystrophin construct
encapsul capsid design deliv muscl
cell high affin possess neuron nitric oxid
synthas nno shown improv blood circul
forc gener muscl function mice base encourag
preclin data believ could translat clinic
meaning result dmd patient dog mice
well toler exhibit immun respons dose test
monkey recov routin anesthet procedur
requir lab work show sign immunogen remain
encourag base safe profil avexi nr
program use vector therefor believ
jame wilson resign scientif advisori board
limited/no read-through
believ could gener disposit clinic
efficaci patient regul investor wait
dmd expect report interim analysi biopsi
clinic measur recent initi ignit studi
link believ data gene therapi
program could posit read
may also choos releas patient-level data earlier
second program antibodi dmd slate
begin preclin develop
dcf discount rate
compani inform leerink partner llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
solid ground public compani initi op
clinic stage biotechnolog compani aim provid cur treatment patient duchenn
muscular dystrophi dmd agnost underli exon mutat would improv srpt
op exondi restor dystrophin limit capac small number dmd patient believ
limit exondi product truncat dystrophin dmd tradit standard
care glucocorticoid make favor posit offer meaning advanc assum high efficaci
found parent whose son dmd compani in-licens gene therapi drug candid
optim microdystrophin construct encapsul capsid design target muscl cell high affin
select among number potenti candid sinc optim three decad
systemat bred stabil muscl forc mice use human cdna specialist develop
believ optim microdystrophin construct base design compar function
express data anim notabl possess neuron nitric oxid synthas nno slow
muscl damag delay fibrosi reduc muscl function loss anim could translat clinic
meaning benefit human far demonstr encourag preclin data posit dystrophin
express via blot immunofluoresc mass spectrometri uniform pattern function data
anim treadmil endur assay immunogen dose test elispot respons
although began experi public compani controversi due compound concern
preclin safeti manufactur resign scientif advisori board sab member retain
attract clinic market potenti view believ issu either adequ
address case preclin safeti manufactur necessarili directli relat sldb
gene therapi program case jame wilson sab resign current interim
ignit data expect second program antibodi dmd anticip enter
preclin develop management guid suffici cash model equiti rais
deriv valuat use discount cash flow dcf
analysi assum discount rate termin
gene therapi dmd antibodi
dmd current estim
gross peak sale
respect account risk clinic regulatori
drug develop probabl success estim
rang us eu
us eu valuat
paramet reflect promis preclin data view off-set
uncertain safety/efficaci profil candid
still rel earli stage develop
balanc sheet debt- chang net other- investing- capex- other- equiti issuanc debt issuanc repay other- dmd dmd total revenue- cogs- total oper incom incom expens incom tax benefit net incom ep basic share dilut share
compar comp analysi gene therapi dmd biotech compani
suggest sldb valuat compel
comp analysi select group biotechnolog compani either dmd gene therapi platform
suggest could credit much higher market capit upon achiev key
clinic catalyst expect next year
address patient dmd main driver
off-set muscl
fatigu
strength eas
solid bioscienc leerink partner equiti research estim
kieni et al annal physic rehabilit medicin jeun et al gene ther method leerink research
us enu us dmd candid receiv antisens pre-exist neutral ab gene therapi penetrance- gross us enu mm us enu mm eu enu eu dmd candid receiv antisens pre-exist neutral ab gene therapi penetrance- gross eu enu mm eu enu mm us eu gross enu mm us eu gross mm probabl success probabl success
model peak revenu us eu adjust probabl success base earli
clinic develop use onc mp luxturna gene therapi price per patient per eye srpt
per patient per year benchmark price model per patient us per patient eu
base sldb preclin data cur potenti
project pt correspond peak market penetr us eu
patient penetr conserv model sinc assum srpt antisens oligonucleotid first
line therapi patient amen exon exon exon skip subtract addit dmd patient
neutral antibodi model believ sldb pan-genotyp therapeut could penetr
remain patient us eu account potenti competit dmd gene
although gene therapi cur potenti may etch away patient popul without sustain repeat
revenu like tradit chronic treatment may still experi sustain growth due larg size
market opportun proactiv patient cultur although forese gene therapi limit factor
consid patient popul decreas provid potenti cur treatment believ premium
price abil address much larger dmd popul exondi could allow sustain revenu growth
longer period time
glucocorticoid exondi may adequ address dmd need due
limit efficaci accordingli opportun may larger efficaci impress
glucocorticoid treatment current standard
care signific limit glucocorticoid
shown temporarili help muscl strength
slow dmd progress leav much room
stunt growth weaken bone structur
recent approv exondi op
question efficaci believ
opportun dmd signific base
strong exondi sale date although exondi
enter market controversi
efficaci data op report sale gain
momentum full year sale
management guid increas
believ sldb exon-agnost dmd drug
candid cur potenti could
transform result demonstr
favor reimburs adjust payor
make exondi believ
gene therapi cur potenti larger dmd
popul like lead higher adopt rate
reimburs exondi recent join unit
op op link
provid treatment patient convers
payor conced posit adopt
sentiment link link know cost
higher price could encount
pushback cur treatment like cost
effect long-term embrac assum
although exondi question efficaci
gener increas sale believ cur
treatment could aggress advoc dmd
patient commun translat high sale
sinc exodi address dmd popul major
dmd patient still unmet medic need believ treatment could
address almost dmd patient like high adopt rate
patient advocaci group increasingli influenti role fda regulatori process dmd patient
advocaci group play pivot role srpt op exondi believ dmd patient advocaci group
continu vocal help support sldb come market
found dad determin find cure son children dmd
found compani demonstr spirit passion dmd patient advocaci commun
ceo ilan ganot creat compani find cure children afflict dmd ultim believ
patient advocaci group benefici
aim deliv portfolio comprehens dmd treatment address dmd patient
focus sole dmd treatment use multipl
approach address entir dmd popul
develop correct therapi disease-modifi therapi
sldb lead program select iter
test mani construct use human cdna sequenc
aim correct faulti dystrophin gene muscl specif
microdystrophin construct systemat optim
stabil forc develop candid
select three decad refin
deliveri synthet transgen shown improv
microdystrophin muscl express function anim
believ three main compon could translat
clinic meaning result base strong preclin data
rigor test develop vector muscl
oxid synthase/nno function improv blood
circul promot drive express muscl
ind-en preclin data posit report
strong express dose respons function kinet toxicolog
data across sever anim model mice dog non-human
primat support potenti clinic util
recent approv exondi op applic
dmd popul amen exon skip yet
garner great interest patient investor
pend clinic efficaci face limit
exclus patient neutral antibodi
immunogen remain seen
encapsul aav
skelet cardiac
diaphragm
deliveri synthet transgen aim
produc dystrophin-lik protein
restor express function
effect target muscl tissu anim
goal specif restor
dystrophin-lik protein muscl sldb preclin
data support broad target muscl tissu
skelet diagraph cardiac
express also muscle-specif
promot shown drive microdystrophin
transgen express muscl skelet diaphragm
cardiac muscl across small larg anim
model consid dmd patient limit
dystrophin deliv microdystrophin muscl could
improv muscl express function
transgen compon select
optim stabil improv muscl
function accord one kol involv
construct systemat test
three decad may translat clinic efficaci
believ microdystrophin
differenti sinc includ neuron nitric oxid
synthas nno demonstr
improv blood circul muscl function mice
believ translat
clinic meaning efficaci investor
regul look
promot muscle-specif promot select abil
drive microdystrophin transgen express skelet diaphragm
transgen transgen addit microdystrophin
domain contain nno bind domain help improv blood
circul muscl function
dose test dmd anim model thu far induc microdystrophin
express dose-depend manner without trigger immun respons
microdystrophin highli express across differ skelet
muscl upper right consid exondi approv
contest due lack efficaci data deliv
signific amount microdystrophin crucial view high
level microdystrophin express cardiac skelet
immunofluoresc stain blot mass spectrometri
dog mice posit
microdystrophin dose-depend manner lower right
dog blot quantif show
wild-typ dystrophin level dose low
vg/kg mid vg/kg high vg/kg dose
respect data also correl microdystrophin level
use mass spectrometri observ immunofluoresc
length dystrophin level dose vg/kg quadricep
heart muscl tissu day
increas microdystrophin across muscl type expect
confer function improv develop
observ uniform dystrophin express result
improv muscl function analog correl muscl
biopsi dog show robust transgen express
immunofluoresc dose level test dog dose
mid-dos vg/kg approxim muscl fiber
posit microdystrophin
safe observ immun respons
dose test dose well toler
observ immun respons transgen dog mice
dose test
level
express
heart skelet
dog
microdystrophin express skelet muscl dog treat sgt-
improv histopatholog think encourag
improv
improv
similar express data muscl function improv dose-depend manner dog figur muscl
forc gener extens flexion torqu improv higher dose test vg/kg and/or vg/kg day
similarli mice mild form dmd anim increas compar untreat mice
distanc travel vg/kg vg/kg respect muscl forc measur ex vivo extensor digitorum
longu muscl exhibit increas untreat control vg/kg vg/kg respect
among mice sever dmd mice treat vg/kg exhibit forc similar wild-typ mice furthermor
anim protect muscl damag associ eccentr contract test known highli damag
muscl integr preserv dose depend fashion dog dmd patient lack dystrophin muscl cell
lose abil repair replac scar tissu fat time ultim lose function dog
preclin data demonstr muscl integr preserv dose depend manner thu earli preclin
data suggest could potenti diseas modifi improv muscl function integr
dystrophin compos main domain vari effect
n-termin domain import
essenti delet
associ mild
phenotyp mice
cysteine-rich domain
import delet
caus sever dystrophi
seem
central rod domain indispens could reduc differ
composit shown vari function effect
mani variat micro- mini-
dystrophin result differ
function outcom
believ differenti construct could deliv meaning efficaci
gene therapi program differ construct may lead differ clinic efficaci
design construct crucial
goal restor dystrophin-lik protein dmd
patient specif dystrophin domain
influenc microdystrophin express
function dystrophin main structur
central rod optim construct would
possess differ domain fit aav
believ differenti
construct three decad effort
creat preclin data mice dog
non-human primat demonstr
deliv muscl high specif
proprietari transgen neuron
nitric oxid synthase/nno improv function
blood circul believ
could translat clinic meaning result
base strong preclin data refin
develop
dystrophin-lik construct intensifi
dmd gene therapi space compet micro-
mini-dystrophin gene therapi candid
emerg efficaci program remain
seen higher express faster approv
could translat higher adopt rate assum
approv race deliv dystrophin-lik
protein continu believ could
well-posit emerg competit
srpt exondi set preced dmd microdystrophin
approv exondi set preced dmd regulatori approv
rout admin
neutral antibodi
srpt/genethon program compar
preclin data may meet undetermin express threshold
perform quantif
dose test
dose test
toxic observ
toxic observ period
wild-typ
show signific
differ treat
control group
ab diff mean
minu pt
antibodi pt
independ adjud determin procedur relat
non-human primat nhp sldb studi euthan
recov routin anesthet procedur
understand investor concern safeti
disclosur via compani amend file link
management believ monkey recov anesthesia
due procedur error cro contract research
organ monkey difficult anim work clinic
 aggress bite carri diseas result
requir anesthesia handl take basic lab measur
base convers management monkey
smallest group happen receiv highest dose
anesthesia day receiv monkey
recov day euthan
adjud compani independ outsid group
fda determin caus procedur error necropsi
data evalu extern peer review toxicologist via cro well
fda agre sldb evalu result
believ safeti concern monkey
fact immunolog abnorm advers event besid
transient asymptomat increas liver function enzym
commonli found receiv gene therapi detect
nhp exhibit fever thrombosi incid seem
isol event unrel nhp die result
immunogen dr wilson studi high dose
modifi vector page t-cell respons
microdystrophin observ either
surviv motor neuron
intraven infus
avx
sldb use
vector
believ could
safe like
use vector avx nr although avx sldb
differ construct differ transgen differ indic use vector sinc
safe believ could safe
avx nr seem safe could bode well potenti safeti clinic admittedli
sma sever diseas low surviv rate sma type patient surviv need
perman ventil support age studi report treatment-rel clinic
asymptomat elev liver function enzym resolv prednisolon treatment total patient
patient report treatment-rel patient report treatment-rel non-treat
relat report well
preclin data demonstr similar safeti profil report transient asymptomat
increas liver function enzym observ nhp start day return normal level day
believ relev test-article-rel advers event ae associ
administr glp good laboratori practic studi
death patient
may led dr wilson
adopt extra cautiou posit
dr wilson patient jess gelsing inject adenoviru vector sldb vector
lead death understand dr wilson outlook gene therapi look clinic
histori unfortun old jess gelsing mild-ornithin transcarbamylas over-the-counter defici inject
gene therapi die death caus immun reaction gene therapi high serum level
cytokin adenovir vector particles/kg dr wilson
leadership clinic trial understand believ dr wilson may develop conserv
stanc gene therapi safeti result
dr wilson concern differ vector valid believ need put proper
context januari dr wilson publish paper hinder et al report nhp piglet
develop sever reaction requir euthanasia dr wilson bring valid safeti concern attent
believ need put proper context pleas refer next slide
raper et al molecular genet metabol emanuel oxford textbook clinic research ethic chapter
anim strong
immun respons requir
euthanasia nhp inject
variant vector
suggest wild-
type variant could safe
diff wild-typ
amino acid insert
amino acid n-terminu
driver could consid safeti gene therapi vector variant dose effect immun respons type
vector variant could okay dose effect immun respons type remain seen
believ sldb vector vector wild-typ variant could safe although small
paper recent publish wilson lab show common theme nhp requir euthanasia
inject vector variant sldb wild-typ vector see fact hordeaux et al
anim inject control construct vector variant wild-typ variant shown gfp
dark blue line requir euthanasia suggest vector variant could potenti
sever provok immun system
dr wilson rais valid safeti concern believ concern need place proper context
seemingli small inconsequenti chang aav could big effect seen drastic immun respons chang
amino acid chang vector lot learn gene therapi remain
mani unknown consist control arm hordeaux et al lead euthan nhp seemingli
safe profil wild-typ variant use avx suggest could safe
dose type immun respons may becom increasingli import
anim given lower
dose variant wild-typ
requir euthanasia
anim receiv
higher dose
gc/kg suggest
dose import
mani drug high dose problemat gene therapi differ may even dose
sensit wilson paper hordeaux et al nhp anim liver function test abnorm
anim receiv higher dose gc/kg counterpart receiv lower dose gc/kg
fact anim receiv lower dose wild-typ variant elicit respons
suggest find optim dose like crucial believ sldb dose elev approach start
lower dose good although may make market later assum approv
final type immun respons innat vs adapt signal time respons
inject could indic sever drug effect earli tell low wilson group
observ immun respons observ fairli quick day inject wilson hinder et al
paper believ time featur toxic note nhp cohort reminisc innat
immun respons high system dose adenovir vector result lethal system inflamm one
research subject jess gelsing earli tell howev dr wilson bring fair concern
time immun respons bear watch
fda place partial clinic hold higher
dose due limit manufactur capabl amend s-
file januari place partial clinic hold sinc
novemb fda reveal manufactur
capabl meet fda requir dose
accord management alreadi resolv
manufactur challeng collect final data
order submit report fda although first lot sgt-
produc rel low yield concentr subsequ lot
perform much better fda want patient receiv
product differ batch case advers event seen
dose singl batch allow adequ attribut
particular manufactur run also fda want high
number vial sinc harder clinician administ
asept increas yield concentr
believ abl advanc higher dose schedul
continu work toward build manufactur
facil suspension-bas process compani
optim past three year intern scientist
contract develop manufactur organ
partner aim integr product manufactur
facil along cdmo commerci product assum
phase i/ii ignit studi commenc studi random control open-
label single-ascend dose studi evalu primari endpoint safeti microdystrophin express efficaci
ambulatori non-ambulatori male age year secondari efficaci endpoint includ muscl function
strength cardiac respiratori function muscl mass area serum muscl biomark associ
microdystrophin product patient report outcomes/qu life measur interim analysi anticip
believ improv microdystrophin ambulatori non-ambulatori patient could maxim
market opportun even small increas microdystrophin could lead benefici outcom
assum safe investor interest microdystrophin express translat muscl function
improv walk test although suffici dose key believ bar need high
patient milder form muscular dystrophi becker muscular dystrophy/bmd could
normal amount/produc partli function dystrophin protein alter size even littl dystrophin impair
muscular dystrophi phenotyp limit believ dmd patient benefit increment even small
amount microdystrophin improv srpt exondi experi would also support idea
believ clinic trial suffici detect efficaci interim data
highli inform mice dystrophin express peak week vector infus muscl function
improv detect month vector infus assum data mice mirror human dmd
progress interim data demonstr improv dystrophin highli encourag forecast possibl
kieni et al annal physic rehabilit medicin jeun et al gene ther method present leerink research
us revenu live us dmd incid dmd median surviv total us dmd candid receiv antisens penetrance- gross us revenu mm us revenu mm eu revenu live eu dmd incid dmd median suviv total eu dmd candid receiv antisens pt address penetrance- gross eu revenu mm eu revenu mm gross us eu revenu mm us eu revenu mm probabl success probabl success
model peak revenu us eu adjust probabl success base
earli clinic develop project pt correspond peak market
penetr us eu patient penetr conserv model antisens
oligonucleotid first line therapi sldb second line therapi assum
cost us eu respect
extend ambul
monoclon antibodi
prevent fibrosi inhibit
cleavag tgf-beta
altern treatment preserv patient ambul base natur histori data dmd patient
homozyg variant remain ambulatori longer patient heterozyg homozyg
vttt variant glucocorticoid-tr patient mean age ambulatori loss year
homozygot vs year vttt heterozygotes/homozygot steroid-na patient mean age
ambulatori loss year homozygot vs year haplotyp sldb second program
leverag observ build comprehens pipelin dmd patient expect enter preclin
develop
aim stabil protein prevent fibrosi inflamm human immunoglobulin
 igg antibodi prevent fibrosi inflamm stabil highli express
muscl inhibit activ tgf-beta pathway preclin vivo efficaci biodistribut safeti
studi begin follow final vitro antibodi character scale-up manufactur effort
flanigan et al annal neurolog compani file
dmd result mutat dystrophin protein predominantli affect boy dmd mutat
dystrophin protein work strengthen protect muscl fiber support proper muscl function
disrupt without properli function dystrophin muscl suffer excess damag daili activ may
regener lead build-up scar fat tissu dystrophin gene mutat
identifi dmd patient inherit x-link manner occur de novo
dmd devast progress irrevers diseas ultim fatal development delay motor
function challeng initi manifest age leg pelvic region motor function
symptom move upward shoulder neck arm usual earli teen dmd patient becom non-
ambulatori becom wheelchair bound dmd patient usual becom paralyz neck
requir ventil breath result motor challeng death occur earli adulthood either
cardiac respiratori complic
manag predict preval case us dmd incid approxim one
everi live male birth
expand intellectu properti strengthen posit dmd
issu pend patent
synthet mini/micro-dystrophin gene restor nno
sarcolemma
foreign patent grant foreign jurisdict china japan europ franc germani great britain ireland hong kong
expir
includ
novel micro-dystrophin relat method use
nucleic acid sequenc encod preptid utrophin
grow ip portfolio us compani exclus licens three
patent three pend two provision one non-provision patent applic foreign
jurisdict seven grant patent pend applic
exclus licens intellectu properti expir exclus
patent famili relat microdystrophin gene includ transgen back-up
construct promot plu transgen combin manufactur trade secret
exclus option licens current ip howev
compani option licens
ilan ganot founder director chief execut offic
senior director diseas research
assist professor muscl age research boston univers school medicin
postdoctor fellow univers pennsylvania
phd univers california lo angel
joel schneider phd chief technolog offic head exploratori research develop
univers pennsylvania
head neurodevelop psychiatri neurosci translat medicin roch
director pain translat medicin johnson johnson
head sale oper north america sr director financ north america philip healthcar
director corpor develop director plan analysi cytyc
senior consult transact servic group pricewaterhousecoop
chang
compani report leerink research
pre-exist neutral ab
address gene therapi
pt
pre-exist neutral ab
address gene therapi
pt
probabl success us
probabl success eu
kieni et al annal physic rehabilit medicin jeun et al gene ther method leerink research
pt
pt address
pt
probabl success us
probabl success eu
kieni et al annal physic rehabilit medicin jeun et al gene ther method present leerink research
